The Ion has implemented a new program that will spark workforce development in Houston. Photo courtesy of the Ion

Houston's The Ion announced this week that it will partner with New York-based Per Scholas as its new workforce development partner.

The partnership is part of the Ion District's Community Benefits Agreement (CBA) that was approved by Houston City Council in late 2021. The $15.3 million agreement aimed to ensure that the 12-block innovation hub developed by Rice University, which is home to the Ion, would benefit all Houstonians, expanding tech jobs while also committing to preserving affordable housing and creating opportunities for minority- and women-owned businesses.

Per Scholas was founded in 1995 and works to advance economic mobility for individuals through its tuition-free training programs, which focus on in-demand tech skills. According to the company, more than 80 percent of those who complete Per Scholas training programs find full-time employment within a year of graduating, and about 85 percent of Per Scholas graduates are people of color.

“Per Scholas is thrilled to join the Ion District and offer our tuition-free tech skills training in Houston,” Plinio Ayala, president and CEO of Per Scholas, said in a statement. “There is such synergy in our approach to innovation and equity. I’m confident that together, we’ll increase opportunity and unlock potential for both individuals and companies that call Houston home."

Per Scholas currently has a campus in downtown Dallas and virtual operations in Houston. It operates out of 20 locations in the U.S.

In addition to announcing the new partnership, the Ion District also released an update on its CBA one year after its launch.

“We’re committed to making Ion District and Ion a catalyst for opportunity, not just for the tech community but city-wide,” Sam Dike, who oversees the CBA’s implementation, said in a statement. “We are proud of the progress thus far. It’s a testament to the community stakeholders who came together to recommend the greatest areas of impact and need. However, this is just the beginning.”

According to the announcement, Ion District is now home to more than 300 businesses. In the next year, the district aims to continue to implement the inclusive hiring, community building, housing affordability and other practices outlined in the CBA.

The organization outlined a few accomplishments in the statement, including:

  • Escrowing $5 million at Unity National Bank, the only certified Minority Depository Institution (MDI) in Texas
  • Contracting opportunities for Ion District Garage, worth $16.9 million, to 19 minority- and women-owned businesses
  • Investing in women and minority tech accelerator and innovation programs, including three DivInc accelerator cohorts
  • Commencing first year of funding for selected housing counseling providers which were: Fifth Ward Community Redevelopment Corporation, Houston Area Urban League and Tejano Center for Community Concerns, to serve the Third Ward, Kashmere Gardens, and Magnolia Park neighborhoods
  • Opening multiple local restaurants at the Ion and in the Ion District that are owned and operated by minority and women chefs and operators
  • Selecting a consulting firm to recommend strategic pathways to achieve MWBE objectives
  • Conducting 10 public outreach events with over 500 minority- and women-owned firms attending
  • Hosting over 130 community-focused events, including Activation Festival, BlackStreet, and additional monthly programming and events accessible to the community

Earlier this month The Ion announced 10 new tenants that were either relocating or expanding their presence in Houston, bringing the total space leased to 86 percent, according to a news release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”